Spotlight on therapeutic efficiency of mesenchymal stem cells in viral infections with a focus on COVID-19.
Saman YasaminehHesam Ghafouri KalajahiPooneh YasaminehOmid GholizadehHamed Rahmani YoushanloueiSaeed Karimi MatloubMasoud MozafariElham JokarYalda YazdaniNosratollah ZarghamiPublished in: Stem cell research & therapy (2022)
The SARS-COV-2 virus has infected the world at a very high rate by causing COVID-19 disease. Nearly 507 million individuals have been infected with this virus, with approximately 1.2% of these patients being dead, indicating that this virus has been out of control in many countries. While researchers are investigating how to develop efficient drugs and vaccines versus the COVID-19 pandemic, new superseded treatments have the potential to reduce mortality. The recent application of mesenchymal stem cells (MSCs) in a subgroup of COVID-19 patients with acute respiratory distress has created potential benefits as supportive therapy for this viral contagion in patients with acute conditions and aged patients with severe pneumonia. Consequently, within this overview, we discuss the role and therapeutic potential of MSCs and the challenges ahead in using them to treat viral infections, with highlighting on COVID-19 infection.
Keyphrases
- sars cov
- mesenchymal stem cells
- umbilical cord
- respiratory syndrome coronavirus
- end stage renal disease
- bone marrow
- coronavirus disease
- newly diagnosed
- chronic kidney disease
- ejection fraction
- cell therapy
- peritoneal dialysis
- prognostic factors
- human health
- risk factors
- early onset
- randomized controlled trial
- risk assessment
- cardiovascular events
- cardiovascular disease
- disease virus
- clinical trial
- coronary artery disease
- climate change
- community acquired pneumonia
- patient reported outcomes
- extracorporeal membrane oxygenation
- phase iii